Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether ultrasound-based assessment of intestinal stiffness in patients with Crohn's disease predicts the effectiveness of medical therapy or the need for surgical resection.


Clinical Trial Description

Modern medical therapy in Crohn's disease, including immunomodulators and biologic compounds, has revolutionized disease treatment. However, a significant portion of individuals will not respond to medications, most often due to the development of intestinal fibrosis. Over the course of Crohn's disease repeated episodes of inflammation and abnormal wound healing lead to progressive intestinal fibrosis, strictures, and bowel obstruction. While inflammatory Crohn's disease often responds to medical therapy, predominantly fibrostenotic intestinal disease is unresponsive and requires surgery. Our inability to accurately distinguish intestinal inflammation from fibrosis frequently leads to empiric trials of steroids and immunosuppressive therapies. This often proves futile, delays inevitable surgery, and unnecessarily exposes the patient to medication-related risks for months and sometimes years. At present there are no available means to distinguish medically responsive inflammatory disease from predominately fibrotic intestinal disease. The unmet need in this field is an accurate diagnostic technology to determine which patients will benefit from anti-inflammatory therapy, and which patients should go directly to surgery. Non-invasive ultrasound stiffness imaging (USI) may be a surrogate marker of underlying bowel wall fibrosis that aids in predicting if Crohn's disease will be responsive to medical therapy.

Two USI methods have recently been developed: Ultrasound elasticity imaging (UEI) uses 2D speckle-tracking to measure tissue strain, a surrogate of fibrosis. The second, shear wave imaging (SWI), is a commercially available technology that measures the speed of ultrasonic shear waves through tissue. Shear waves travel more rapidly through stiff tissue. The central hypothesis of this proposal is that ultrasound stiffness imaging (USI) quantitatively distinguishes predominately inflammatory from fibrotic bowel wall thickening, and therefore is predictive of the likelihood of response to medical therapy or the need for surgery.

We plan to objectively test our central hypothesis and attain the objective of this application by pursuing the following three specific aims:

Specific Aim 1 (SA-1): Determine if USI stiffness measurements of intestinal strictures in Crohn's patients admitted with small bowel obstruction predicts response or failure of medical therapy based on CDAI and objective inflammatory biomarkers during index hospitalization and at 90 day follow-up.

Inpatient Inclusion Criteria:

- Subjects must be 18 years of age or older

- Previous diagnosis of Crohn's disease with imaging demonstrating involvement of the ileum

- Hospital admission imaging demonstrating small bowel dilation (to > 3.5 cm)

- CDAI score of >220.

Inpatient Exclusion Criteria:

- Active Clostridium difficile colitis/enteritis

- Presence of abdominal enterocutaneous fistulas in the ultrasound path.

- Prior abdominal hernia repair with mesh placement in the ultrasound path.

Specific Aim 2 (SA-2): Determine if USI stiffness measurements of diseased ileum in Crohn's outpatients starting Anti-Tumor Necrosis Factor-Alpha therapy predicts response to medical therapy based on CDAI and objective inflammatory biomarkers.

Outpatient Inclusion Criteria

- Crohn's patients age 18 and over starting anti-TNF therapy

- CDAI score > 220 to denote clinical disease activity.

Outpatient Exclusion Criteria:

- Active Clostridium difficile colitis/enteritis

- Presence of abdominal enterocutaneous fistulas in the ultrasound path

- Prior abdominal hernia repair with mesh placement in the ultrasound path

- Current use of prednisone or budesonide

- Changing anti-TNF due to allergy (including a TNF-induced lupus-like arthritis). ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01666626
Study type Observational
Source University of Michigan
Contact
Status Completed
Phase N/A
Start date September 2012
Completion date July 2015

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01958827 - A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease Phase 3